Aquilo Capital Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Aquilo Capital Management, LLC reported 13 stock positions worth $88.8 million. Its top holding was Arrowhead Pharmaceuticals (ARWR) at 17.4% of the portfolio, followed by Blueprint Medicines (BPMC, 13.0%) and Kymera Therapeutics (KYMR, 11.1%). Compared with Q2 2024, it added to 5 and reduced 5. The biggest buy was Immatics (IMTX, shares +67%) and the biggest sale Arrowhead Pharmaceuticals (ARWR, shares −12%).
- Most Recent 13F
- Q3 2025
- Location
- SAN FRANCISCO, CA
- CIK
- 0001591986
- Portfolio Value
- $88.8M (Q3 2024)
- SEC Filing
- 0001591986-24-000007 ↗ filed Nov 14, 2024
Holdings Value
Holdings 13 stocks · $88.8M
| ARWR Arrowhead Pharmaceuticals Inc. | 17.35% | 795,813 | $15.4M | Reduce -12.4% |
| BPMC Blueprint Medicines Corp. | 12.97% | 124,600 | $11.5M | Add +8.7% |
| KYMR Kymera Therapeutics Inc. | 11.12% | 208,743 | $9.9M | Reduce -36.5% |
| RGNX Regenxbio Inc. | 10.99% | 930,708 | $9.8M | Add +2.7% |
| ARVN Arvinas Inc. | 10.78% | 388,766 | $9.6M | Reduce -9.3% |
| MRUS Merus NV | 6.63% | 117,855 | $5.9M | Reduce -20.4% |
| SLN Silence Therapeutics PLC-ADR | 6.49% | 317,214 | $5.8M | Reduce -36.6% |
| BCYC Bicycle Therapeutics PLC-ADR | 4.63% | 181,911 | $4.1M | Add +16.1% |
| IMTX Immatics NV | 4.28% | 333,502 | $3.8M | Add +66.8% |
| ACET Adicet Bio Inc. | 4.10% | 2,531,194 | $3.6M | No change |
| DTIL Precision Biosciences Inc. | 3.85% | 381,803 | $3.4M | No change |
| RPTX Repare Therapeutics Inc. | 3.83% | 989,364 | $3.4M | Add +3.4% |
| STRO Sutro Biopharma Inc. Com SHS | 2.97% | 762,498 | $2.6M | No change |
Options reported separately and not counted above: SPY puts ($43.0M).
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
Options Activity Q2 2024 → Q3 2024
| SPY SS SPDR S&P 500 ETF Trust-US | put | New | 75,000 | $43.0M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.